- Home
- PCSA vs IVDA Comparison
PCSA vs IVDA Comparison
Compare PCSA & IVDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCSA
- IVDA
- Stock Information
- Founded
- PCSA 2011
- IVDA 2003
- Country
- PCSA United States
- IVDA United States
- Employees
- PCSA N/A
- IVDA N/A
- Industry
- PCSA Biotechnology: Pharmaceutical Preparations
- IVDA Computer Software: Prepackaged Software
- Sector
- PCSA Health Care
- IVDA Technology
- Exchange
- PCSA Nasdaq
- IVDA Nasdaq
- Market Cap
- PCSA 4.3M
- IVDA 3.7M
- IPO Year
- PCSA N/A
- IVDA N/A
- Fundamental
- Price
- PCSA $0.86
- IVDA $2.15
- Analyst Decision
- PCSA Buy
- IVDA
- Analyst Count
- PCSA 3
- IVDA 0
- Target Price
- PCSA $5.00
- IVDA N/A
- AVG Volume (30 Days)
- PCSA 26.8K
- IVDA 551.7K
- Earning Date
- PCSA 10-30-2024
- IVDA 11-14-2024
- Dividend Yield
- PCSA N/A
- IVDA N/A
- EPS Growth
- PCSA N/A
- IVDA N/A
- EPS
- PCSA N/A
- IVDA N/A
- Revenue
- PCSA N/A
- IVDA $5,305,154.00
- Revenue This Year
- PCSA N/A
- IVDA $23.76
- Revenue Next Year
- PCSA N/A
- IVDA $229.89
- P/E Ratio
- PCSA N/A
- IVDA N/A
- Revenue Growth
- PCSA N/A
- IVDA N/A
- 52 Week Low
- PCSA $0.85
- IVDA $1.27
- 52 Week High
- PCSA $17.40
- IVDA $10.16
- Technical
- Relative Strength Index (RSI)
- PCSA 21.42
- IVDA 63.26
- Support Level
- PCSA $0.85
- IVDA $1.50
- Resistance Level
- PCSA $1.06
- IVDA $1.56
- Average True Range (ATR)
- PCSA 0.08
- IVDA 0.27
- MACD
- PCSA -0.02
- IVDA 0.10
- Stochastic Oscillator
- PCSA 2.89
- IVDA 71.54
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its "regulatory science" approach in the development of Next Generation Chemotherapy ("NGC") oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small molecule oncology drugs. The NGC products are new chemical entities, but the company work by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are - NGC-Capecitabine (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
About IVDA Iveda Solutions Inc.
Iveda Solutions Inc is engaged in offering real-time IP video surveillance technologies. The company provides IoT sensors and devices for various applications such as energy management, smart homes, smart buildings, smart communities, and patients and eldercare. Its IvedaAI provides AI functions to IP cameras and network video recorders and video management systems. The group has a business presence in the U.S. and the Republic of China (Taiwan), from which key revenue is derived from the Republic of China (Taiwan).